Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06937996 · ClinicalTrials.gov registry record
Outcomes of Ablation of Unresectable Pancreatic Cancer Using the NanoKnife Irreversible Electroporation System-
A clinical trial of Pancreatic Cancer Non-resectable, sponsored by Englewood Hospital and Medical Center.
- Recruiting
- Registry status
- 25
- Enrollment target
- 1
- Study location
NCT06937996: Recruiting study of Pancreatic Cancer Non-resectable, sponsored by Englewood Hospital and Medical Center.
NCT06937996 is a study of Pancreatic Cancer Non-resectable that is actively recruiting participants, run by Englewood Hospital and Medical Center. The registered enrollment target is 25 participants, below the 38-participant average among 4 other Pancreatic Cancer Non-resectable trials with a reported enrollment target (34% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06937996, a study of Pancreatic Cancer Non-resectable, is actively recruiting participants, sponsored by Englewood Hospital and Medical Center.
- RECRUITING
- Registry status
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the short and intermediate term safety of the NanoKnife Irreversible Electroporation System when used off-label to treat unresectable pancreatic cancer. In addition, the study will evaluate the efficacy of this device in treating pain associated with unresectable pancreatic cancer. Quality of life post-procedure will also be collected.
Primary Outcome
Safety and tolerability of the procedure by monitoring the number of participants with Adverse Events at the following time points: 1, 2, 4, 7, 14, 21 and 30 days and 3, 6, 9, 12, 15, 18, 21, and 24 months post-IRE procedure. The primary endpoint will be the number of Participants with an adverse event related to the IRE treatment and serious or non-serious, at least grade 3, at least possibly related to treatment This will be measured by a series of questionnaires on pain scores via Quality of
Conditions Studied
Interventions
- DEVICE NanoKnife
Study Locations (1)
New Jersey
- Englewood Hospital - Englewood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2025-05-13 |
| Est. Completion | 2035-05-31 |
What NCT06937996 shows while recruiting
NCT06937996 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 38-participant average among 4 other Pancreatic Cancer Non-resectable trials with a reported enrollment target (34% lower).
The record links to 1 condition, with Pancreatic Cancer Non-resectable appearing as the primary indexed condition, and to 1 intervention - of which NanoKnife is the first listed.
NCT06937996 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT06937996 about?
NCT06937996 is a clinical study titled "Outcomes of Ablation of Unresectable Pancreatic Cancer Using the NanoKnife Irreversible Electroporation System-". The purpose of this study is to evaluate the short and intermediate term safety of the NanoKnife Irreversible Electroporation System when used off-label to treat unresectable pancreatic cancer. In addition, the study will evaluate the efficacy of this device in treating pain associated with unresect...
What is the current status of trial NCT06937996?
This trial is currently recruiting. The enrollment target is 25 participants. The study started on 2025-05-13. Estimated completion is 2035-05-31.
What conditions does trial NCT06937996 study?
This clinical trial studies the following conditions: Pancreatic Cancer Non-resectable.
What interventions are being tested in trial NCT06937996?
The interventions under investigation include: NanoKnife (DEVICE).
Who is sponsoring clinical trial NCT06937996?
This trial is sponsored by Englewood Hospital and Medical Center, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06937996 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer Non-resectable
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
Medical Cannabis in Patients With Advanced Pancreatic and Colorectal Cancer
RECRUITING · Phase 2
-
Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)
ACTIVE NOT RECRUITING · Phase 1
-
INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI